AKASA recognized for achievements in automating healthcare operations with AI and ML
December 8, 2021 — NEW YORK — CB Insights today named AKASA to its third annual Digital Health 150, which showcases the 150 most promising private digital health companies in the world. This year’s Digital Health 150 was unveiled live during CB Insights’ annual Future of Health event.
The 2021 Digital Health 150 cohort has raised roughly $14.9B in aggregate funding across 522 deals since 2016, and includes startups at various investment stages of development, from early-stage to well-funded unicorns. Companies this year include startups working on data integration & analytics, hybrid virtual / in-person care, digital therapeutics, clinical intelligence, and more.
“This year’s Digital Health 150 is one of our most expansive yet, spotlighting 16 categories including virtual care, clinical trials tech, and workflow automation, as well as adding new categories such as home health tech and computer-aided imaging,” said Brian Lee, SVP of CB Insights’ Intelligence Unit. “Last year’s class has seen more than 20 exits, raised an additional $18.6B in aggregate funding, and announced over 250 partnerships since being recognized, and we’re excited to see the future success of this year’s winners.”
“For the second year in a row, we’re thrilled to be recognized by CB Insights as one of the top digital health companies,” said Malinka Walaliyadde, co-founder and CEO of AKASA. “Our purpose is to enable human health as we build the future of healthcare with AI. AKASA scales human intelligence with leading-edge AI and ML to eliminate administrative burden and reduce operating costs so that health systems can allocate resources to where they matter most.”
Through an evidence-based approach, the CB Insights research team selected the Digital Health 150 from a pool of over 11,000 companies, including applicants and nominees. They were chosen based on several factors, including data submitted by the companies, company business models and momentum in the market, and Mosaic scores, CB Insights’ proprietary algorithm that measures the overall health and growth potential of private companies.
Earlier this year, AKASA announced it raised $60 million in its Series B funding round, bringing total funding to $85 million. AKASA’s customer base represents more than $100 billion in aggregate net patient revenues which equates to nearly 10 percent of all U.S. health system spending annually, according to data from the Centers for Medicaid and Medicare Services. Additionally, the company’s models and algorithms have been trained on nearly 250 million claims and remittances.
2021 Digital Health 150 Investment Highlights:
CB Insights builds software that enables the world’s best companies to discover, understand, and make technology decisions with confidence. By marrying data, expert insights, and work management tools, clients manage their end-to-end technology decision-making process on CB Insights. To learn more, please visit www.cbinsights.com.
AKASA is the leading developer of AI for healthcare operations. AKASA scales human intelligence with leading-edge AI and ML securely trained on customer data to learn unique systems, continuously adapt to changing environments, and deliver comprehensive automation and analytics for complex workflows. The result is a seamlessly integrated, customized solution that reduces operating costs, frees up staff to do the work they love, and helps health systems allocate resources to where they matter most.
AKASA has a work-from-anywhere attitude and we are hiring. Step into the future of healthcare with AKASA. Learn more at www.AKASA.com.
Media Contact
Kate Enos
Director of Media Relations
AKASA
[email protected]
916.397.6400